[1] Hatakeyama S. TRIM family proteins: roles in autophagy, immunity, and carcinogenesis[J]. Trends Biochem Sci, 2017, 42(4): 297-311. DOI: 10.1016/j.tibs.2017.01.002.
[2] Esposito D, Koliopoulos MG, Rittinger K. Structural determinants of TRIM protein function[J]. Biochem Soc Trans, 2017, 45(1): 183-191. DOI: 10.1042/BST20160325.
[3] Zhang Z, Xu C, Zhang X, et al. TRIM11 upregulation contributes to proliferation, invasion, and EMT of hepatocellular carcinoma cells[J]. Oncol Res, 2017, 25(5): 691-699. DOI: 10.3727/096504016X14774897404770.
[4] Zhou Z, Liu Y, Ma M, et al. Knockdown of TRIM44 inhibits the proliferation and invasion in papillary thyroid cancer cells through suppressing the Wnt/βcatenin signaling pathway[J]. Biomed Pharmacother, 2017, 96: 98-103. DOI: 10.1016/j.biopha.2017.09.132.
[5] Kang KJ, Ahn KS. Anatomical resection of hepatocellular carcinoma: a critical review of the procedure and its benefits on survival[J]. World J Gastroenterol, 2017, 23(7): 1139-1146. DOI: 10.3748/wjg.v23.i7.1139.
[6] Erstad DJ, Tanabe KK. Hepatocellular carcinoma: earlystage management challenges[J]. J Hepatocell Carcinoma, 2017, 4: 81-92. DOI: 10.2147/JHC.S107370.
[7] Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis[J]. J Carcinog, 2017, 16: 1. DOI: 10.4103/jcar.JCar_9_16.
[8] Chao J, Zhang XF, Pan QZ, et al. Decreased expression of TRIM3 is associated with poor prognosis in patients with primary hepatocellular carcinoma[J]. Med Oncol, 2014, 31(8): 102. DOI: 10.1007/s12032-014-0102-9.
[9] Huang XQ, Zhang XF, Xia JH, et al. Tripartite motifcontaining 3 (TRIM3) inhibits tumor growth and metastasis of liver cancer[J]. Chin J Cancer, 2017, 36(1): 77. DOI: 10.1186/s40880-017-0240-5.
[10] Chen Y, Li L, Qian X, et al. High expression of TRIM11 correlates with poor prognosis in patients with hepatocellular carcinoma[J]. Clin Res Hepatol Gastroenterol, 2017, 41(2): 190-196. DOI: 10.1016/j.clinre.2016.09.010.
[11] Li L, Dong L, Qu X, et al. Tripartite motif 16 inhibits hepatocellular carcinoma cell migration and invasion[J]. Int J Oncol, 2016, 48(4): 1639-1649. DOI: 10.3892/ijo.2016.3398.
[12]Ding Q, He D, He K, et al. Downregulation of TRIM21 contributes to hepatocellular carcinoma carcinogenesis and indicates poor prognosis of cancers[J]. Tumour Biol, 2015, 36(11): 8761-8772. DOI: 10.1007/s13277-015-3572-2.
[13] Liu X, Huang Y, Yang D, et al. Overexpression of TRIM24 is associated with the onset and progress of human hepatocellular carcinoma[J]. PLoS One, 2014, 9(1): e85462. DOI: 10.1371/journal.pone.0085462.
[14] Jiang S, Minter LC, Stratton SA, et al. TRIM24 suppresses development of spontaneous hepatic lipid accumulation and hepatocellular carcinoma in mice[J]. J Hepatol, 2015, 62(2): 371-379. DOI: 10.1016/j.jhep.2014.09.026.
[15] Wang Y, He D, Yang L, et al. TRIM26 functions as a novel tumor suppressor of hepatocellular carcinoma and its downregulation contributes to worse prognosis[J]. Biochem Biophys Res Commun, 2015, 463(3): 458-465. DOI: 10.1016/j.bbrc.2015.05.117.
[16] Wang Y, Jiang J, Li Q, et al. KAP1 is overexpressed in hepatocellular carcinoma and its clinical significance[J]. Int J Clin Oncol, 2016, 21(5): 927-933. DOI: 10.1007/s10147016-0979-8.
[17] Jin X, Pan Y, Wang L, et al. MAGETRIM28 complex promotes the Warburg effect and hepatocellular carcinoma progression by targeting FBP1 for degradation[J]. Oncogenesis, 2017, 6(4): e312. DOI: 10.1038/oncsis.2017.21.
[18] Cassano M, Offner S, Planet E, et al. Polyphenic trait promotes liver cancer in a model of epigenetic instability in mice[J]. Hepatology, 2017, 66(1): 235-251. DOI: 10.1002/hep.29182.
[19] Guo P, Ma X, Zhao W, et al. TRIM31 is upregulated in hepatocellular carcinoma and promotes disease progression by inducing ubiquitination of TSC1-TSC2 complex[J]. Oncogene, 2018, 37(4): 478488. DOI: 10.1038/onc.2017.349.
[20] Liu J, Zhang C, Wang XL, et al. E3 ubiquitin ligase TRIM32 negatively regulates tumor suppressor p53 to promote tumorigenesis[J]. Cell Death Differ, 2014, 21(11): 1792-1804. DOI: 10.1038/cdd.2014.121.
[21] Cui X, Lin Z, Chen Y, et al. Upregulated TRIM32 correlates with enhanced cell proliferation and poor prognosis in hepatocellular carcinoma[J]. Mol Cell Biochem, 2016, 421(1-2): 127137. DOI: 10.1007/s11010-016-2793-z.
[22] Chen Z, Lu X, Wang Z, et al. Coexpression of PKM2 and TRIM35 predicts survival and recurrence in hepatocellular carcinoma[J]. Oncotarget, 2015, 6(4): 2538-2548. DOI: 10.18632/oncotarget.2991.
[23] Chen Z, Wang Z, Guo W, et al. TRIM35 Interacts with pyruvate kinase isoform M2 to suppress the Warburg effect and tumorigenicity in hepatocellular carcinoma[J]. Oncogene, 2015, 34(30): 3946-3956. DOI: 10.1038/onc.2014.325.
[24] Song L, Zhang W, Chang Z, et al. miR4417 targets tripartite motifcontaining 35 (TRIM35) and regulates pyruvate kinase muscle 2 (PKM2) phosphorylation to promote proliferation and suppress apoptosis in hepatocellular carcinoma cells[J]. Med Sci Monit, 2017, 23: 1741-1750. DOI: 10.12659/MSM.900296.
[25] Jiang J, Yu C, Chen M, et al. Overexpression of TRIM37 promotes cell migration and metastasis in hepatocellular carcinoma by activating Wnt/betacatenin signaling[J]. Biochem Biophys Res Commun, 2015, 464(4): 1120-1127. DOI: 10.1016/j.bbrc.2015.07.089.
[26] Zhu X, Wu Y, Miao X, et al. High expression of TRIM44 is associated with enhanced cell proliferation, migration, invasion, and resistance to doxorubicin in hepatocellular carcinoma[J]. Tumour Biol, 2016, 37(11): 14615-14628. DOI: 10.1007/s1327701653163.
[27] Zhang Y, Wu SS, Chen XH, et al. Tripartite motif containing 52 (TRIM52) promotes cell proliferation in Hepatitis B virusassociated hepatocellular carcinoma[J]. Med Sci Monit, 2017, 23: 5202-5210.
[28] Qiu X, Huang Y, Zhou Y, et al. Aberrant methylation of TRIM58 in hepatocellular carcinoma and its potential clinical implication[J]. Oncol Rep, 2016, 36(2): 811-818. DOI: 10.3892/or.2016.4871.
[29] Yang YF, Zhang MF, Tian QH, et al. TRIM65 triggers βcatenin signaling via ubiquitylation of Axin1 to promote hepatocellular carcinoma[J]. J Cell Sci, 2017, 130(18): 3108-3115. DOI: 10.1242/jcs.206623. |